Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M

Emmaus Life Sciences, Inc.

2026-Q1 EPS reported -$0.05 revenue$1,982,000

Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.
Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.
MENA segment sales surged 446%, partially offsetting U.S. decline.
Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Emmaus Life Sciences, Inc. reported three months ended March 31, 2026 results: revenue $2.0 million, net income $3.3 million, EPS $0.05 basic net loss per share.

Period: three months ended March 31, 2026
Revenue: $2.0 million
Net income: $3.3 million
EPS: $0.05 basic net loss per share
Result: reported results

Exact text from the filing

Net revenues for the three months ended March 31, 2026 were $2.0 million, compared to $2.4 million in the same period in 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-057828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.